Tag Archives: Evercore ISI

Pfizer, Merck’s Bavencio flop illustrative of shattered Pharma model. Is industry’s collapse just around the corner?

The News: Pfizer Inc. (NYC) and its German part­ner Merck KGaA (Darmstadt) have run into a brick wall in their race to ex­pand the mar­ket for their PD-L1 check­point inhibitor Baven­cio… Read more »

Biogen’s poster presentation for Alzheimer’s candidate hardly noticed at London AAIC meeting as market focuses on quarterly results instead; start accumulating.

Biogen Inc. (Cambridge MA) laid out long-term plans to strengthen its core multiple sclerosis (MS) business, develop more neuroscience drugs and shop for late-stage assets, after reporting robust second-quarter results,… Read more »

Trump tweet on drug prices sinks pharma shares; what’s next, doctors’ wages? Not.

Steve’s Take: President Trump’s morning ritual continues to enthrall millions, but occasionally causes Wall Street analysts covering the pharma industry to reach for their bottle of Maalox. After House Republicans… Read more »

Teva’s CEO Vigodman history; sudden departure calls for fearless successor

The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) suddenly found itself without a permanent CEO on Tuesday (February 7, 2017) after Erez Vigodman stepped down, leaving new management to… Read more »

Walgreens cuts offer for Rite Aid, casting doubt on merger; analysts say deal still alive

The News: Walgreens Boots Alliance (Deerfield IL) on Monday (January 30, 2017) entered into a new agreement with Rite Aid (Camp Hill PA) to buy the drugstore chain for at least $2 less per share… Read more »

Feds charge Heritage execs with price fixing; DOJ ringing out 2016 on a roll against Pharma offenses

The former chief executive and former president of generic drug company Heritage Pharmaceuticals Inc. (Eatontown, NJ) have been charged with conspiring to fix prices, the first charges in a continuing… Read more »

Lilly Alzheimer’s drug, like so many others, fails; will true breakthrough happen this century?

Eli Lilly & Co. (Indianapolis RIN) said its experimental Alzheimer’s treatment failed to slow loss of cognitive ability in patients with mild symptoms, a major setback for the company and millions of… Read more »

Valeant stock plunges anew on dismal 3Q results; behold another pharma Sisyphus

After an already noisy year, Valeant Pharmaceuticals International Inc. (Laval Québec) once again took investors off guard–this time, on Election Day–as new management cut the annual profit forecast to well… Read more »

Mylan’s EpiPen faces competition from Kaleo Pharma; just what the doctor ordered

Privately held drugmaker Kaleo Inc. (Richmond VA), the main competitor to Mylan NV’s (Amsterdam) EpiPen, announced plans on Wednesday (October 26, 2016) for a US relaunch of its Auvi-Q injector… Read more »

Bristol Myers Clobbered as Cancer Drug Disappoints; Rival Merck Unanimous Winner at Medical Conference

New data are likely to prompt doctors to abandon Bristol-Myers Squibb Co.’s (New York City) immunotherapy Opdivo in favor of Merck & Co.’s (Kenilworth NJ) rival Keytruda in a large… Read more »